The Role of Antiplatelet Agents in Patients with Peripheral Vascular Disease

Kannel WB McGee DL . Update on some epidemiologic features of intermittent claudication: The Framingham Study. J Am Geriatr Soc 1985; 33: 13–18.

Blombery PA . Intermittent Claudication: An update on management. Drugs 1987; 34: 404–10.

McDaniel MD Cronenwett JL . Basic data related to the natural history of intermittent claudication. Ann Vasc Surg 1989; 3: 273–77.

Criqui MH Fronek A Barret-Connor E Klauber MR Gabriel S Goodman D. The prevalence of peripheral arterial disease in a defined population. Circulation 1985; 71: 510–15.

Verhaerghe R Bounameaux H. Peripheral arterial occlusion: Thromboembolism and antithrombotic therapy. In: Fuster V Verstraete M eds. Thrombosis in cardiovascular disorders. Philadelphia: WB Saunders, 1992: 423–49.

Criqui MH Langer RD Fronek A Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992; 326: 381–86.

Smith GD Shipley MJ Rose G. Intermittent claudication, heart disease risk factors, and mortality: The Whitehall Study. Circulation 1990; 82: 1925–31.

Woolf N Davies MJ . Interrelationship between atherosclerosis and thrombosis. In: Fuster V Verstraete M eds. Thrombosis in cardiovascular disorders. Philadelphia: WB Saunders, 1992: 41–77.

Mustard JF Packham MA Kinlough-Rathbone RL . Platelets, blood flow and the vessel wall. Circulation 1990; 81 (suppl I): I-24–I-27.

Moran N Fitzgerald GA . Mechanisms of action of antiplatelet drugs. In: Colman RW Hirsh J Marder VJ Salzman EW eds. Hemostasis and thrombosis. Philadelphia: JB Lippincott, 1994; 1623–37.

Fuster V Badimon L Badimon JJ Chesebro JH . The pathogenesis of coronary artery disease and the acute coronary syndromes (second of two parts). N Engl J Med 1992; 326: 310–18.

Badimon L Badimon JJ Fuster V. Pathogenesis of thrombosis. In: Fuster V Verstraete M eds. Thrombosis in cardiovascular disorders. Philadelphia: WB Saunders, 1992: 17–39.

Fuster V Chesebro JH . Series on pharmacology in practice: 10. Antithrombotic therapy: Role of platelet-inhibitor drugs. II. Pharmacologic effects of platelet-inhibitor drugs (second of three parts). Mayo Clin Proc 1981; 56: 185–95.

Fitzgerald GA . Mechanisms of platelet activation: Thromboxane A₂ as an amplifying signal for other agonists. Am J Cardiol 1991; 68: 11B–15B.

Cameron HA Waller PC Ramsay LE . Drug treatment of intermittent claudication: A critical analysis of the methods and findings of published clinical trials, 1965–1985. Br J Clin Pharmacol 1988; 26: 569–76.

Duprez D Clement DL . Medical treatment of peripheral vascular disease: Good or bad? Eur Heart J 1992; 13: 149–51.

Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989; 321: 129–35.

Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy — I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308: 81–106.

Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330: 1287–94.

Goldhaber SZ Manson JE Stampfer MJ Low-dose aspirin and subsequent peripheral arterial surgery in the Physicians' Health Study. Lancet 1992; 340: 143–45.

Hess H Mietaschk A Deichsel G. Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease: A prospective double-blind arteriographically controlled trial. Lancet 1985; i: 415–19.

Fitzgerald GA . Dipyridamole. N Engl J Med 1987; 316: 1247–57.

Stein B Fuster V. Clinical pharmacology of platelet inhibitors. In: Fuster V Verstraete M eds. Thrombosis in cardiovascular disorders. Philadelphia: WB Saunders, 1992: 99–119.

Green D Miller V. The role of dipyridamole in the therapy of vascular disease. Geriatrics 1993; 48: 46–58.

McTavish D Faulds D Goa KL . Ticlopidine: An updated review of its pharmacology and therapeutic use in platelet-dependent disorders. Drugs 1990; 40: 238–59.

The Medical Letter on Drugs and Therapeutics. Ticlopidine for prevention of stroke. Med Lett Drugs Ther 1992; 34: 65–66.

Bourde C Eschwwege E Verry M. Controlled clinical trial of an antiaggregating agent: Ticlopidine in vascular ulcers of the leg [Abstact]. Thromb Haemost 1981; 46: 91.

Katsumura T Mishima Y Kamiya K Sakaguchi S Tanabe T. Therapeutic effect of ticlopidine, a new inhibitor of platelet aggregation, on chronic arterial occlusive diseases, a double-blind study versus placebo. Angiology 1982; 33: 357–67.

Arcan JC Blanchard J Boissel JP Destors JM Panak E. Multicenter double-blind study of ticlopidine in the treatment of intermittent claudication and the prevention of its complications. Angiology 1988; 39: 802–11.

Balsano F Coccheri S Libretti A Ticlopidine in the treatment of intermittent claudication: A 21-month double-blind trial. J Lab Clin Med 1989; 114: 84–91.

Cloarec M Caillard PH Mouren X. Double-blind clinical trial of ticlopidine versus placebo in peripheral atherosclerotic disease of the legs [Abstract]. Thromb Res 1986; 42 (suppl 6): 160.

Boissel JP Peyrieux JC Destors JM . Is it possible to reduce the risk of cardiovascular events in subjects suffering from intermittent claudication of the lower limbs? Thromb Haemost 1989; 62: 681–85.

Janzon L Bergquist D Boberg J Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicenter Study. J Intern Med 1990; 227: 301–308.

Blanchard J Carreras LO Kindermans M. Results of EMATAP: A double-blind placebo-controlled multicentre trial of ticlopidine in patients with peripheral vascular disease. Nouv Rev Fr Hematol 1993; 35: 523–28.

Brogden RN Sorkin EM . Ketanserin: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease. Drugs 1990; 40: 903–49.

De Cree J Leempoels J Geukens H Verhaegen H. Placebo-controlled double-blind trial of ketanserin in treatment of intermittent claudication. Lancet 1984; ii: 775–79.

Bounameaux H Holditch T Hellemans H Berent A Verhaeghe R. Placebo-controlled, double-blind, two-center trial of ketanserin in intermittent claudication. Lancet 1985; ii: 1268–71.

Cameron HA Waller PC Ramsay LE . Placebo-controlled trial of ketanserin in the treatment of intermittent claudication. Angiology 1987; 38: 549–55.

Walden R Bass A Rabi I Adar R. Randomized placebo-controlled, double-blind trial of ketanserin in treatment of intermittent claudication. J Cardiovasc Surg 1991; 32: 737–40.

Prevention of Atherosclerotic Complications with Ketanserin Trial Group. Prevention of atherosclerotic complications: Controlled trial of ketanserin. Br Med J 1989; 298: 424–30.

PACK Claudication Substudy Investigators. Randomized placebo-controlled, double-blind trial of ketanserin in claudicants: Changes in claudication distance and ankle systolic pressure. Circulation 1989; 80: 1544–48.

Grant SM Goa KL . Iloprost: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischemia and extracorporeal circulation procedures. Drugs 1992; 43: 889–924.

European working Group on Critical Leg Ischemia. Second European consensus document on chronic critical leg ischemia. Circulation 1991; 84 (suppl IV): IV-I–IV-26.

Ernst E. Pentoxifylline for intermittent claudication: A critical review. Angiology 1994; 45: 339–45.

Spittell JA . Pentoxifylline and intermittent claudication. Ann Intern Med 1985; 102: 126–27.

De Felice M Gallo P Masotti G. Current therapy of peripheral obstructive arterial disease. The nonsurgical approach. Angiology 1990; 41: 1–11.

Radack K Wyderski RJ . Conservative management of intermittent claudication. Ann Intern Med 1990; 113: 135–46.

Wiseman LR Fitton A Buckley MM . Indobufen: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in cerebral, peripheral and coronary vascular disease. Drugs 1992; 44: 445–64.

Belcaro G De Simone P. Long-term evaluation of indobufen in peripheral vascular disease. Angiology 1991; 42: 8–14.

Signorini GP Salmistraro G Maraglino G. Efficacy of indobufen in the treatment of intermittent claudication. Angiology 1988; 39: 742–45.

Coto V Cocozza M Oliviero U Clinical efficacy of picotamide in long-term treatment of intermittent claudication. Angiology 1989; 40: 880–85.

Uchikawa T Murakami T Furukawa H. Effects of the anti-platelet agent cilostazol on peripheral vascular disease in patients with diabetes mellitus. Arzneimittelforschung 1992; 42: 322–24.

Veith FJ Gupta SK Ascer E. Six-year prospective multicenter randomized comparison of autologous saphenous vein and expanded polytetrafluoroethylene grafts in infrainguinal arterial reconstructions. J Vasc Surg 1986; 3: 104–13.

Green RM Roedersheimer LR DeWeese JA . Effects of aspirin and dipyridamole on expanded polytetrafluoroethylene graft patency. Surgery 1982; 92: 1016–26.

Goldman M Hall C Dykes J Hawker RJ McCollum CN . Does ¹¹¹indium-platelet deposition predict patency in prosthetic arterial grafts? Br J Surg 1983; 70: 635–38.

Clyne CAC Archer TJ Atuhaire LK Chant ADB Webster JHH . Random control trial of a short course of aspirin and dipyridamole (persantin) for femorodistal grafts. Br J Surg 1987; 74: 246–48.

Kohler TR Kaufman JL Kacoyanis G Effect of aspirin and dipyridamole on the patency of lower extremity bypass grafts. Surgery 1984; 96: 462–66.

Clagget CP Graor RA Salzman EW . Antithrombotic therapy in peripheral arterial occlusive disease. Chest 1992; 102 (suppl): 516S–28S.

McCollum C Alexander C Kenchington G Franks PJ Greenhalgh R. Antiplatelet drugs in femoropopliteal vein bypasses: A multicenter trial. J Vasc Surg 1991; 13: 150–62.

Cunningham DA Kumar B Siegel BA Gilula LA Totty WG Welch MJ . Aspirin inhibition of platelet deposition at angioplasty sites: Demonstration by platelet scintigraphy. Radiology 1984; 151: 487–90.

Heiss HW Just H Middleton D Deichsel G. Reocclusion prophylaxis with dipyridamole combined with acetylsalicylic acid following PTA. Angiology 1990; 41: 263–69.

Mahler F Schneider E Gallino A Bollinger A. Combination of suloctidil and anticoagulation in the prevention of reocclusion after femoropopliteal PTA. Vasa 1987; 16: 381–85.

Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy—II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. Br Med J 1994; 308: 159–68.